Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927457 | 0.81 | MRGPRX4 (0.68) | MRGPRX4RAB9ASMN1; SMN2PLA2G4B | |
| SCHEMBL7336764 | 0.79 | ALDH1A1 (0.67) | PLA2G4BPTPN11 | |
| SCHEMBL2928667 | 0.78 | HSD17B10 (0.69) | MRGPRX4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL1199847 | 0.77 | ALDH1A1 (0.69) | PLA2G4BPTPN11 | |
| SCHEMBL9512861 | 0.77 | ALDH1A1 (0.65) | PLA2G4BPTPN11 | |
| SCHEMBL1231278 | 0.77 | ALDH1A1 (0.69) | PLA2G4BPTPN11 | |
| SCHEMBL1201602 | 0.77 | ALDH1A1 (0.69) | PLA2G4BPTPN11 | |
| SCHEMBL1200986 | 0.77 | ALDH1A1 (0.69) | PLA2G4BPTPN11 | |
| SCHEMBL1199892 | 0.77 | ALDH1A1 (0.69) | PLA2G4BPTPN11 | |
| SCHEMBL1199953 | 0.77 | ALDH1A1 (0.69) | PLA2G4BPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653134-B2 | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| EP-1836150-B1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | claimed |
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | MERCK PATENT GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| EP-1836150-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | Merck Patent GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006074798-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-07-20 | — | — | WO | claimed |
| US-8653134-B2 | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-1836150-B1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | MERCK PATENT GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | PPARG, PPARA, PPARD | MRGPRX4 888/4885NPC1 1307/4885LMNA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.